Physician profile
Shira Ehrlich
NPI 1679129068
$6,756.59
in general payments reported to CMS, 2019-2025
25 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $1,915 · 2023: $1,157 · 2024: $1,510 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,392.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.26 | 2021-2025 | |
| Lilly USA, LLC | $804.86 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $609.60 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $599.25 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $583.97 | 2023-2024 | Vtama |
| Genzyme Corporation | $438.30 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $383.99 | 2022-2025 | |
| Amgen INC. | $284.40 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $275.21 | 2024-2025 | Aklief, Nemluvio |
| Incyte Corporation | $232.98 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $185.16 | 2022-2024 | Simponi Aria, Tremfya, Stelara |
| Sun Pharmaceutical Industries INC. | $167.55 | 2021-2022 | |
| Botanix Sb INC | $162.01 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $145.95 | 2022-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $144.32 | 2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $116.70 | 2022 | |
| Janssen Scientific Affairs, LLC | $108.29 | 2022 | |
| Ucb, INC. | $88.54 | 2022-2024 | Bimzelx |
| Organon LLC | $73.06 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $49.41 | 2024 | Xtrac |
| Verrica Pharmaceuticals INC. | $27.52 | 2025 | Ycanth |
| Kyowa Kirin, INC. | $23.75 | 2021 | |
| Leo Pharma INC. | $20.92 | 2021 | |
| Cipher Pharmaceuticals US LLC | $18.50 | 2025 | Natroba, Spinosad |
| Biofrontera INC. | $18.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shira Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.